echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > PLoS Genet: identify a key molecule that can effectively inhibit the growth and spread of melanoma

    PLoS Genet: identify a key molecule that can effectively inhibit the growth and spread of melanoma

    • Last Update: 2020-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    January 19, 2020 / biool / -- recently, in a research report published in the international journal PLoS Genetics, scientists from the University of bath found a special molecule, which may effectively inhibit the growth of melanoma; although the research is still in the early stage, relevant research results may help scientists develop new methods to resist Melanoma and other types of cancer Photo source: Wikipedia / cc by-sa 3.0 incrnas is a special molecule transcribed from body DNA, which does not express protein At present, researchers are not clear about the function of these incrnas In this study, researchers have conducted in-depth research on a class of incrnas involved in cancer; they are in a group with melanoma Among 245 incrnas involved in genesis, a molecule named dirc3 (disrupted in nal carcinoma 3) was identified, which may play the role of tumor suppressor, thus effectively blocking the spread of human melanoma in the experiment By using gene editing technology to turn off the generation of dirc3, the researchers found that the rate of tumor independent growth, the marker of cancer spread, increased by 2-8 times; dirc3 was able to turn on the expression of IGFBP5 gene, the key tumor suppressor, which revealed its key role in a variety of complex networks, which controlled the The expression of genes is very important for the growth and diffusion of melanoma In this study, researchers used clinical data from the cancer genome map to link the expression of dirc3 with the prognosis of patients with melanoma They found that compared with patients with lower expression level of dirc3, the survival rate of patients with melanoma producing high level of dirc3 increased significantly Researcher Keith Vance said that although the study is at an early stage, we are very pleased that the use of drugs that activate dirc3 may be a new way to help treat skin cancer In recent years, scientists have made great progress in melanoma research However, not all patients will respond to the current treatment, and most skin cancer patients will have tolerance to the treatment over time Therefore, researchers urgently need to develop a new treatment for skin cancer In this study, by clarifying the working mechanism of dirc3, researchers may be able to understand how it blocks the progress of melanoma at the molecular level, which is crucial for the later development of new targeted therapy for melanoma Original source: Elizabeth A Coe, Jennifer y Tan, Michael Shapiro, et al The mitf-sox10 regulated long non coding RNA dirc3 is a Mexico tumour supervisor, PLoS Genetics (2019) Doi: 10.1371/journal.pgen.1008501
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.